You are here

Press Releases from AlphaMed Press

Comment

Discuss

Embargo Policy: Articles for STEM CELLS and STEM CELLS Translational Medicine are embargoed for release until 9 a.m. Eastern U.S. time on the day the article is posted online. This policy applies to members of the media, authors, institutions' public information officers, and the public. Authors may not discuss their work with the media until 1 week before the mailing date or 1 week before online posting of the article, whichever is earlier, and must ensure that the media representatives agree to abide by the embargo policy. STEM CELLS Translational Medicine may refuse to publish a manuscript, despite acceptance for publication, if it has been prematurely released to the press.

March 19, 2014

Researchers have discovered what appears to be an easy way to collect large quantities of viable stem cells that can be banked for future regenerative medicine purposes – all from the simple prick of a finger. The study results were published online in STEM CELLS Translational Medicine.

“We show that a single drop of blood from a finger-prick sample is sufficient for performing cellular reprogramming, DNA sequencing and blood typing in parallel. Our strategy has the potential of facilitating the development of large-scale human iPSC banking worldwide,” said Jonathan Yuin-Han Loh, Ph.D., of the Agency for Science, Technology and Research (A*STAR) in Singapore. He is principal investigator on the study that also included scientists from other Singapore facilities as well as those in the United States and Great Britain.   

February 20, 2014

A new study released today in STEM CELLS Translational Medicine shows that many patients with defects to the skull, face or jaw bone might benefit from reconstructive surgery combining stem cells taken from adipose (fat) tissue seeded on resorbable scaffolds.

These defects can be due to congenital malformations, such as cleft lip and palate, or to traumatic injuries or surgery to remove a tumor. The use of a patient’s own bone is still considered the gold standard for reconstructing these defects, but this requires yet another surgery to harvest the bone for the reconstructive procedure. The STEM CELLS Translational Medicine study tracked the case of 13 patients undergoing regenerative medicine procedures.

February 4, 2014

STEM CELLS is proud to announce the appointment of new Associate Editor, Dr. Toru Kondo of Hokkaido University, Japan. Dr. Kondo has served as an outstanding member of the STEM CELLS Editorial Board since 2007 and we are delighted that he has accepted our invitation to become an Associate Editor. He joins Associate Editors, Dr. Majlinda Lako and Dr. Noel Buckley, Concise review Editor Dr. Terry Lappin, and Editor Dr. Jan Nolta.

February 3, 2014

Previous studies have shown that multiple stem cell implantations might assist adults suffering from complete spinal cord injuries (SCI). Now a groundbreaking study released today in STEM CELLS Translational Medicine shows for the first time that children with SCI might benefit, too.

Marcin Majka, Ph.D., and Danuta Jarocha, Ph.D., led the study at Jagiellonian University College of Medicine in Krakow, Poland. “Although it was conducted on a small number of patients carrying a different injury level and type, preliminary results demonstrate the possibility of attaining neurological, motor and sensation and quality-of-life improvement in children with a chronic complete spinal cord injury through multiple bone marrow derived cell (BMNC) implantations. Intravenous implantations of these cells seem to prevent and/or help the healing of pressure ulcers,” Dr. Majka said.

January 29, 2014

In a study just published in STEM CELLS Translational Medicine, researchers have found what might prove to be a rich new source of adult stem cells for use in regenerative medicine — the tissue normally discarded during routine hip replacement surgery. With well over 300,000 hip replacements taking place each year in the United States alone, according to the Centers for Disease Control, this tissue might provide an unprecedented source of autologous stem cells for aging patients and have “profound implications” in clinical use, the scientists say.

January 20, 2014

January 17, 2014 - A new assessment tool is helping scientists determine which treatments might benefit patients with a type of eye disorder called limbal stem cell deficiency (LSCD). The tool, developed by researchers at University College London and Moorfields Eye Hospital in London and funded by the UK’s National Institute for Health Research Biomedical Research Centre at these institutions, has already shown that the majority of these patients can benefit in the short term from a stem cell transplantation and up to 30 percent are still experiencing better sight three years later, according to the study published in the current issue of STEM CELLS Translational Medicine.

January 14, 2014

A new study released in STEM CELLS Translational Medicine indicates that stem cells can be effective in treating a debilitating and sometimes lethal genetic disorder called brittle bone disease.

Brittle bone disease, or osteogenesis imperfecta (OI), is characterized by fragile bones causing some patients to suffer hundreds of fractures over the course of a lifetime. In addition, according to the OI Foundation, other symptoms include muscle weakness, hearing loss, fatigue, joint laxity, curved bones, scoliosis, brittle teeth and short stature. Restrictive pulmonary disease occurs in the more severe cases. Currently there is no cure.

December 19, 2013

A new study released today in STEM CELLS Translational Medicine demonstrates that the therapeutic value of stem cells collected from fat declines when the cells come from older patients.

“This could restrict the effectiveness of autologous cell therapy using fat, or adipose-derived mesenchymal stromal cells (ADSCs), and require that we test cell material before use and develop ways to pretreat ADSCs from aged patients to enhance their therapeutic potential,” said Anastasia Efimenko, M.D., Ph.D. She and Nina Dzhoyashvili, M.D., were first authors of the study led by Yelena Parfyonova, M.D., D.Sc.,at Lomonosov Moscow State University, Moscow.

December 9, 2013

Generating new cardiac muscle from human embryonic stem cells (hESCs) and/or induced pluripotent stem cells (iPSC) could fulfill the demand for therapeutic applications and drug testing. The production of a similar population of these cells remains a major limitation, but in a study just published in STEM CELLS Translational Medicine, researchers now believe they have found a way to do this.

By combining small molecules and growth factors, the international research team led by investigators at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai developed a two-step system that caused stem cells to differentiate into ventricular heart muscle cells from hESCs and iPSCs. The process resulted in high efficiency and reproducibility, in a manner that mimicked the developmental steps of normal cardiovascular development.

December 4, 2013

A new study appearing in STEM CELLS Translational Medicine (SCTM) demonstrates the potential of a subset of stem cell called CD34+ in treating hard to heal bone fractures.

While most patients recover from broken bones with little or no complication, up to 10 percent experience fractures that won’t heal. This can lead to a number of debilitating side effects, from infection to bone loss, and it can require extensive treatment involving multiple operations and prolonged hospitalization as well as long-term disability.

Regenerating broken bone using stem cells could offer an answer. Adult human peripheral blood CD34+ cells have been shown to contain an abundance of a type of stem cell called endothelial progenitor cells (EPCs) as well as hematopoietic stem cells, which give rise to all types of blood cells. As such, they could be good candidates for this therapy.

Pages